CEL-SCI reports 73.4% five-year survival in Multikine Phase 3 patient analysis

Podcast: Proactive - Interviews for investors · Proactive

Opublikowano: 2026-10-30

he findings were presented by CEL-SCI Chief Scientific Officer and Multikine developer Dr. Eyal Talor during a keynote address at the 6th World Congress on Otology, Rhinology and Laryngology in Rome, Italy. The analysis focused on pre-surgical patient stratification, an approach intended to identify patients most likely to benefit from immunotherapy before undergoing surgery, radiation or chemotherapy. Traditionally, risk assessment in head and neck cancer has relied heavily on pathological findings obtained after surgery, potentially limiting opportunities to tailor treatment earlier in the care pathway. By examining disease characteristics and pre-treatment tumor biomarkers associated with Multikine’s mechanism of action, CE...